OC-001 is a CD137 mAb agonist designed to show differential agonistic activity from that of competitor
antibodies. OC-001 provided T cell activation that results in antitumor efficacy in humanized mouse
tumor models in vivo.
Primary objective: to assess the safety and tolerability of OC-001 administered as a monotherapy in
patients with selected locally advanced or metastatic cancer.
Secondary objective: to evaluate the PK of OC-001 after single and multiple dose administration.
By, Wilson H Miller, Diane Provencher, Quincy Chu, Derek Jonker, Gerald Batist, Rahima Jamal, Rakesh Goel, John Hilton, Jennifer Spratlin, Patricia S. Smith, Inger Darling, Sara Zaknoen, John R. Stille, Caroline Fortier, and Rupi Mangat.
Poster presented at the ESMO Congress; September 9 – 13, 2022; Paris, France.